+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are studying participants with active systemic lupus erythematosus SLE, including those with lupus nephritis, who have not responded adequately to glucocorticoids and at least two immunosuppressant therapies. The aim is to characterize the effectiveness and safety of current standard of care treatments for this condition. This observational study focuses on understanding how these treatments work in real-world settings for patients with active disease. Participants receive treatments based on the current standard of care according to product guidelines, including biologic therapies among other immunosuppressants. The study specifically includes those with active disease confirmed by clinical assessments and positive autoantibodies. Participants with lupus nephritis must have had a recent renal biopsy showing specific active kidney involvement. Treatment and observation continue over several years to evaluate long-term outcomes. During the study, participants undergo evaluations at regular intervals up to 60 months. Researchers assess disease remission, kidney function, disease activity scores, flare frequency, and patient-reported fatigue. Data collection involves clinical assessments, laboratory tests, and questionnaires to measure treatment response and safety. This long-term follow-up provides insight into how well patients maintain remission and respond to standard therapies over time.

Age: 16Years +All Genders
70 locations
S

Actively Recruiting

Researchers are evaluating the effects of experimental drugs pozelimab and cemdisiran in adults aged 50 to 85 with Geographic Atrophy GA caused by Age-related Macular Degeneration AMD, a condition affecting central vision. The study aims to compare the progression rate of GA in patients treated with cemdisiran alone, pozelimab combined with cemdisiran, and a placebo, while also examining side effects, drug levels in the blood, and immune responses to the drugs. Participants are randomly assigned to one of three groups pozelimab plus cemdisiran, cemdisiran alone, or placebo. All treatments are given by subcutaneous injection. The study is double-masked and placebo-controlled, lasting up to 104 weeks for key outcome measures, with extended safety monitoring up to 296 weeks. The trial includes multiple visits for evaluations and treatments over this period. During the study, participants undergo detailed eye imaging using Fundus Autofluorescence to measure GA lesion growth, assessments of visual acuity, and contrast sensitivity tests at weeks 52 and 104. Blood samples are collected to measure drug concentrations and immune responses, including antibodies against the drugs. Safety is monitored throughout the study and during extended follow-up. Participants adherence to clinic visits and vaccinations is required for participation.

Age: 50Years - 85YearsAll GendersPhase 3
231 locations
E

Actively Recruiting

Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.

Age: 18Years +All GendersPhase 3
188 locations
E

Actively Recruiting

Researchers are studying targeted therapies for adults with moderately to severely active Rheumatoid Arthritis RA, a chronic condition causing joint pain, stiffness, swelling, and loss of function. This Phase 2 trial aims to evaluate the safety and effectiveness of three different treatment approaches compared to placebo in participants who have not responded well to one or two prior biologic or targeted synthetic disease-modifying antirheumatic drugs btsDMARDs. The study includes three substudies Lutikizumab monotherapy versus placebo, Ravagalimab monotherapy versus placebo, and a combination of Lutikizumab and Ravagalimab versus placebo. Treatments are given as subcutaneous injections with participants randomized to receive either active drugs or matching placebo doses. Approximately 180 participants will enroll and receive study treatments during the trial. Participants will have regular visits at hospitals or clinics where medical assessments, blood tests, side effect monitoring, and questionnaires will be conducted. The main outcomes measured include the percentage of participants achieving significant improvement in RA symptoms American College of Rheumatology 50% response at 12 weeks and tracking adverse events up to about 22 weeks. The study continues until November 2027 with ongoing safety and efficacy monitoring.

Age: 18Years +All GendersPhase 2
96 locations
E

Actively Recruiting

Researchers are evaluating the medicine BI 3000202 in adults with moderate to severe systemic lupus erythematosus SLE to find out if it helps manage the condition. This phase II study randomly assigns participants to one of five groups, including four different doses of BI 3000202 and one placebo group. The goal is to determine the best dose while monitoring the safety and effects of the medicine. Participants take their assigned tablets daily for one year while continuing their regular SLE treatments. The study involves a randomized, placebo-controlled, double-blind design with parallel groups. Four groups receive varying doses of BI 3000202, and one group receives placebo tablets that look the same but contain no medicine. During the study, participants visit the study site regularly for health checks, monitoring of any side effects, and assessments of their disease activity using tools like the Systemic Lupus Erythematosus Responder Index. The study lasts a bit longer than one year, allowing thorough evaluation of treatment effects and safety. Researchers compare results among the groups to understand the medicines impact on SLE.

Age: 18Years - 74YearsAll GendersPhase 2
139 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the effect of early administration of tranexamic acid TXA on blood loss in adults with intracapsular and extracapsular hip fractures undergoing surgery. The study aims to assess whether giving TXA as soon as possible after diagnosis, in addition to the usual intraoperative dose, reduces perioperative blood loss and the need for postoperative blood transfusions. This investigation is conducted at a Level II trauma center and is sponsored by Ascension Health. The study has two groups one group receives 1 gram of TXA soon after diagnosis plus an additional gram during surgery, totaling 2 grams the other group receives only the intraoperative dose of 2 grams. TXA is given intravenously, with one dose infused before incision and the other at wound closure. Participants are randomly assigned to one of these groups to compare outcomes. Participants will be monitored for up to two weeks after surgery to measure outcomes like overall blood loss, need for blood transfusions, length of hospital stay, postoperative pain, wound complications, and occurrence of acute deep vein thrombosis or pulmonary embolism. The study involves assessments during hospital stay and follow-up to track these measures and ensure participant safety.

Age: 18Years +All GendersPhase 2Phase 3
1 location
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of ianalumab in adolescents and adults with systemic lupus erythematosus who have previously completed treatment in one of two core SIRIUS-SLE studies. This extension study focuses on participants with moderate-to-severe disease activity and positive anti-nuclear antibodies. The study is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by Novartis Pharmaceuticals. The study involves three treatment periods over up to 7 years a 3-year double-blind phase where participants receive ianalumab subcutaneously either monthly or quarterly, or a monthly placebo followed by a 2-year period assessing safety and efficacy of treatment withdrawal and open-label monthly ianalumab and finally, an open-label safety monitoring period lasting up to 2 years. Participants receive the treatments subcutaneously as scheduled during each period. Participants will be closely monitored throughout the study, with assessments covering adverse events, disease activity responses, damage indices, corticosteroid use, and antibody levels. The primary measure is the number of treatment-emergent adverse events or serious adverse events up to about 324 weeks. Regular evaluations include clinical assessments, laboratory tests, and serum measurements. The total study duration for participants may extend up to 7 years, including long-term safety follow-up.

Age: 12Years - 100YearsAll GendersPhase 3
164 locations
R

Actively Recruiting

Researchers are studying the best timing for vitrectomy surgery to remove symptomatic epiretinal membranes ERM, a condition affecting the retina that can cause visual distortion and loss. The trial compares immediate surgery to deferred surgery, which is usually recommended when vision worsens to 2040 or worse. The study aims to understand how delaying surgery impacts visual outcomes, identify factors predicting surgery success or disease progression, and evaluate new measures of visual distortion and reading speed in this condition. Participants are randomly assigned to one of two groups immediate vitrectomy surgery within one month of randomization, or deferred vitrectomy where surgery is performed only if vision declines significantly, symptoms worsen, or complications arise. The deferred group is closely monitored to detect changes that would trigger surgery. This approach helps researchers compare outcomes between early and delayed surgical intervention for ERM. During the study, participants undergo regular vision assessments, including evaluating visual acuity changes over 36 months, which is the primary outcome measure. Researchers also collect data on visual distortion and reading speed to better understand symptoms. Safety and progression are closely monitored, and surgery timing decisions are guided by defined criteria or participant preference. The total study duration extends up to three years, providing long-term insight into ERM management.

Age: 45Years +All GendersPhase Not Applicable
49 locations
O

Actively Recruiting

This trial focuses on participants with autoimmune and inflammatory conditions who have previously taken part in a Novartis study involving secukinumab. It aims to evaluate the long-term safety of secukinumab in those who continue to benefit from the treatment but cannot access the marketed version. The study is a Phase 4, open-label extension designed to provide ongoing assessment of this medication. Participants will receive secukinumab injections under the skin at doses of 75 mg, 150 mg, or 300 mg every four weeks, depending on their previous treatment dose in the parent trial. Pediatric dosing will be limited according to weight categories and prior evaluated maximum doses. Investigators can adjust doses based on clinical needs and health authority guidance. This study involves a single group receiving secukinumab with no placebo or comparator. During the study, participants will be monitored for up to two years to assess the occurrence of any adverse or serious adverse events. The trial will involve regular evaluations to track the participants safety while continuing secukinumab treatment. The total duration for participation can extend until the study ends in 2030, with ongoing safety assessments throughout this period.

Age: 6Years - 100YearsAll GendersPhase 4
171 locations

1-10 of 11

1